Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

An experimental antibiotic protocol for serious open fractures isn't raising red flags — at least not yet. Interim data from a multicenter trial show the SEXTANT protocol, which uses targeted systemic antibiotics plus topical vancomycin and tobramycin, produced very few complications among 232 patients. Researchers caution that final conclusions must wait until the trial is unblinded.
An experimental antibiotic strategy for lower extremity open fractures appears to be well-tolerated based on early trial data, offering cautious optimism for orthopedic trauma surgeons battling stubbornly high infection rates.
Interim results from an ongoing prospective multicenter trial, presented at the Orthopaedic Trauma Association Annual Meeting, evaluated the METRC SEXTANT protocol against standard prophylactic care in 232 patients with type III open fractures below the knee. The SEXTANT approach involves at least 72 hours of wound bioburden-targeted systemic antibiotics, combined with topical vancomycin and tobramycin powder applied at final wound closure.
Researchers tracked antibiotic-related complications including acute kidney injury, C. difficile colitis, renal insufficiency, and allergic reactions. The results so far are reassuring — though definitive conclusions about efficacy await full unblinding.
By the Numbers:
Why it matters: Open fracture infections are costly, debilitating, and notoriously difficult to prevent. If the SEXTANT protocol proves both safe and effective, it could meaningfully shift how orthopedic trauma teams approach antibiotic prophylaxis.